5.02
-0.47(-8.56%)
Currency In USD
| Previous Close | 5.49 |
| Open | 5.05 |
| Day High | 5.46 |
| Day Low | 5.02 |
| 52-Week High | 27.5 |
| 52-Week Low | 4.06 |
| Volume | 20,880 |
| Average Volume | 11,558 |
| Market Cap | 15.19M |
| PE | -0.04 |
| EPS | -135.78 |
| Moving Average 50 Days | 4.96 |
| Moving Average 200 Days | 11.22 |
| Change | -0.47 |
Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results
GlobeNewswire Inc.
Nov 14, 2024 9:30 PM GMT
COVID: Phase 1 pharmacokinetic profile supports the potential for ratutrelvir to be dosed as a once-a-day, single drug, 10-day treatment course, without ritonavir, and with a lower likelihood of clinical rebound and good overall tolerabilityFlu: Phas
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
GlobeNewswire Inc.
Oct 08, 2024 11:30 AM GMT
Investigational agent in development as a one dose treatment or prevention of seasonal and pandemic influenza A dose ranging, Phase 1 study in healthy volunteers demonstrated positive tolerability results and plasma levels in the predicted therapeuti
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
GlobeNewswire Inc.
Sep 30, 2024 11:30 AM GMT
Ratutrelvir was well-tolerated for 10 days and achieved consistent plasma levels in the predicted therapeutic window, without the need for co-administration of ritonavir Phase 2a study expected to begin in H1 2025 in patients with COVID Improving COV